Results of #TheOnestudy trial just released @TheLancet

Multiple regulatory cell therapy including autologous tolerogenic dendritic cells (ATDCs) in Nantes @CRTI_Nantes and ITUN @CHUnantes were tested in phase I/II kidney transplant trials. The main conclusion is that regulatory cell therapy is achievable and safe in living-donor kidney transplant recipients, and is associated with fewer infectious complications, but similar rejection rates in the first year. We are proud to have been part of this amazing international collaborative effort headed by Ed Geissler.

The paper on the generation of ATDCs just released as well @TransplantJrnl